Agustí Alvar, Calverley Peter M, Decramer Marc, Stockley Robert A, Wedzicha Jadwiga A
Institut del Tòrax, Hospital Clínic, Barcelona, Spain.
Clinical Sciences Center, University Hospital Aintree, Liverpool, United Kingdom.
Chronic Obstr Pulm Dis. 2014 Sep 25;1(2):166-184. doi: 10.15326/jcopdf.1.2.2014.0134.
The 2011 recommendations of the Global initiative for chronic Obstructive Lung Disease (GOLD) constituted a major paradigm shift in COPD management since they set 2 major goals for the assessment and management of patients: the reduction of their current level of symptoms (i.e., treat the patient ); and the reduction of their risk of exacerbations (i.e., prevent them ). Exacerbations are not only an important clinical endpoint in patients with COPD, but they are also a risk factor themselves for additional adverse outcomes since they have been shown to increase the risk for mortality, to accelerate the decline in pulmonary function, and to decrease health status and quality of life. Despite their importance, many unanswered questions related to exacerbations remain. The purpose of this review is to discuss: and in our current understanding of exacerbations, what known factors increase their risk, and how to best prevent them.
慢性阻塞性肺疾病全球倡议组织(GOLD)2011年的建议在慢性阻塞性肺疾病(COPD)管理方面构成了重大的范式转变,因为它们为患者的评估和管理设定了两个主要目标:降低其当前症状水平(即治疗患者);以及降低其急性加重风险(即预防急性加重)。急性加重不仅是慢性阻塞性肺疾病患者的一个重要临床终点,而且它们本身也是导致其他不良后果的一个危险因素,因为已表明它们会增加死亡风险、加速肺功能下降,并降低健康状况和生活质量。尽管急性加重很重要,但许多与急性加重相关的未解决问题仍然存在。本综述的目的是讨论:在我们目前对急性加重的理解中,哪些已知因素会增加其风险,以及如何最好地预防急性加重。